The technology is underpinned by twenty years of research led by Professor Robyn O’Hehir and her team at Alfred Health and Monash University, which has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust, and the National Health and Medical Research Council. The novel technology uses carefully selected fragments of peanut proteins to switch off allergic reactions. These fragments do not contain the parts of the nut proteins that cause the life-threatening anaphylactic reactions that make many other proposed peanut allergy therapeutics unsafe. Unlike other approaches, this technology would not need life-long daily dosing. A successful treatment would have a global impact, and could transform the lives of thousands of children and adults. The Company is headquartered in Melbourne, Australia.
About Peanut Allergy
Peanut allergy is a rapidly growing problem in Australia and around the world. When exposed to peanuts, sufferers can experience a range of symptoms, from mild itchiness and rash to life-threatening anaphylaxis, with swelling and blockage of the airways and critically low blood pressure. About one person in every fifty is allergic to peanuts, and every year about half of these suffer a serious, potentially life-threatening reaction to peanuts that cannot be predicted or prevented. Fatalities are fortunately rare, but allergy sufferers live in constant fear of an accidental peanut encounter.
Aravax aims to safely revolutionise the lives of those with peanut allergy by removing the risk of life-threatening reactions to peanuts.
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The treatment will use new technology that can reset the immune system to tolerate peanut without evoking allergic reactions during treatment.